A unified framework for pre-screening and screening tools in oncology clinical trials

Clinical trial enrollment in oncology remains limited by increasingly complex eligibility criteria, biomarker stratification, and fragmented clinical data, contributing to prolonged recruitment timelines and low participation rates. This review examines contemporary pre-screening and screening approaches, spanning manual workflows, health-system-embedded digital tools, and emerging artificial intelligence-enabled methods. We assess the relative strengths and limitations of large language model-based strategies, including retrieval-augmented and domain-adapted approaches, in addressing scalability, accuracy, and equity challenges. Hybrid frameworks that integrate automated screening with clinician oversight appear most effective in improving trial matching efficiency, representativeness, and timely access to investigational therapies across diverse oncology populations.

Authors

Institutions

Publication Details

Journal
npj Precision Oncology
Published
2026-01-30
DOI
https://doi.org/10.1038/s41698-026-01306-3
Primary Topic
Cancer Genomics and Diagnostics
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A unified framework for pre-screening and screening tools in oncology clinical trials

Denis Horgan, Frédérique Penault Lorca, V. Subbiah, Arturo Loaiza-Bonilla et al.
npj Precision Oncology
Cancer Genomics and Diagnostics
article

A unified framework for pre-screening and screening tools in oncology clinical trials

Denis Horgan, Frédérique Penault Lorca, V. Subbiah, Arturo Loaiza-Bonilla, Christer Svedman, Paul Hofman, Daniel Schneider, Hadi Mohamad Abu Rahsheed, Joe Paulson, Stan Kachnowsk, Umberto Malapelle
article en

Abstract

Clinical trial enrollment in oncology remains limited by increasingly complex eligibility criteria, biomarker stratification, and fragmented clinical data, contributing to prolonged recruitment timelines and low participation rates. This review examines contemporary pre-screening and screening approaches, spanning manual workflows, health-system-embedded digital tools, and emerging artificial intelligence-enabled methods. We assess the relative strengths and limitations of large language model-based strategies, including retrieval-augmented and domain-adapted approaches, in addressing scalability, accuracy, and equity challenges. Hybrid frameworks that integrate automated screening with clinician oversight appear most effective in improving trial matching efficiency, representativeness, and timely access to investigational therapies across diverse oncology populations.

npj Precision Oncology
St. Luke's University Health Network (US), Qatar Airways (Qatar) (QA), Johnson & Johnson (United States) (US), Exelixis (United States) (US), Université Clermont Auvergne (FR), Sam Higginbottom Institute of Agriculture (IN), Yale University (US), Emergency University (US), Sarah Cannon (US), Centre Jean Perrin (FR), Hôpital Pasteur (FR), Massey University (NZ), University of Naples Federico II (IT), Columbia University (US)
Openalex Percentile: Top 72%
Cancer Genomics and Diagnostics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

A unified framework for pre-screening and screening tools in oncology clinical trials — Denis Horgan, Frédérique Penault Lorca, et al. · npj Precision Oncology (2026) | TGRS Research Map | TGRS